<DOC>
	<DOCNO>NCT03022565</DOCNO>
	<brief_summary>This proof-of-concept study evaluate ability vorinostat induce transformation Class 2 uveal melanoma cell cell phenotype resembles normal melanocyte .</brief_summary>
	<brief_title>Vorinostat Patients With Class 2 High Risk Uveal Melanoma</brief_title>
	<detailed_description>This proof concept , single-center , open-label study FDA-approved drug , vorinostat , Histone deacetylase ( HDAC ) inhibitor , patient Class 2 , high-risk uveal melanoma localize eye tumor . The primary aim test vorinostat transform aggressive class 2 uveal melanoma cell cell look like normal melanocyte observe laboratory . Uveal melanoma patient meet inclusion criterion outline protocol consent ask provide fine needle aspiration ( FNA ) biopsy uveal melanoma primary tumor . This biopsy submit gene expression analysis determine phenotype tumor . A total 10 patient meet criterion Class 2 uveal melanoma radiologic evidence metastasis treat 400 mg vorinostat daily 15 day . On Day 15 , patient ask provide second FNA biopsy prior receive standard care local definitive therapy either plaque radiotherapy enucleation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Uveal melanoma tumor determine ophthalmic ultrasound clinical assessment . 2 . Class 2 uveal melanoma 3 . No evidence metastatic disease . 4 . Age ≥18 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 6 . Life expectancy great 3 month . 7 . Able swallow retain orallyadministered medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowels 8 . Patients must normal organ marrow function define : Absolute neutrophil count ( ANC ) &gt; 1,500 cells/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 10.0g/dL Aspartate transaminase ( AST ) and/or Alanine transaminase ( ALT ) &lt; 3x upper limit normal ( ULN ) Total bilirubin &lt; 2x ULN Hemoglobin A1C ≤ 5.7 % Alkaline phosphatase &lt; 3x ULN Serum creatinine &lt; 2x ULN creatinine clearance &gt; 60 mL/min Note : Patients hyperbilirubinemia clinically consistent inherit disorder bilirubin metabolism ( e.g. , Gilbert syndrome ) eligible discretion treat physician and/or principal investigator . 9 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation 4 month completion study drug administration . Women childbearing potential must negative serum urine test time enrollment . Men treat enrol protocol must also agree use adequate contraception prior study , duration study therapy , 4 month completion study drug administration . 10 . Willingness comply visit procedure ( include provide biological specimen ) require protocol inform consent form ( ICF ) . 11 . Ability understand investigational nature , potential risk benefit research study provide valid write informed consent . 1 . Definitive therapy primary uveal melanoma either surgery radiotherapy 2 . History another malignancy except diseasefree 3 year , patient history completely resect nonmelanoma skin cancer and/or patient indolent secondary malignancy require active therapy , eligible . Consult study Principal Investigator unsure whether second malignancy meet requirement specify . 3 . Any major surgery extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior initiation study therapy . 4 . History prior vorinostat use . 5 . Use investigational drug within 28 day 6 . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate vorinostat ( i.e . HDAC inhibitor hydroxamates panobinostat belinostat ) . 7 . A QT interval correct ( QTc ) heart rate use Bazett 's formula ( QTcB ) ≥ 480 msec . Concurrent administration vorinostat agent cause QTc prolongation permit . 8 . Concurrent administration vorinostat HDAC inhibitor permit due increase risk thrombocytopenia gastrointestinal bleeding . 9 . Patients combination antiretroviral therapy ineligible potential pharmacokinetic interaction vorinostat . 10 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 11 . History pulmonary embolism ( PT ) deepvein thrombosis ( DVT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Uveal Melanoma</keyword>
</DOC>